Clinical Trial Update: Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating an SGLT2 inhibitor for major depressive disorder is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• SGLT2 inhibitor

Snippet

Sponsor: NYU Langone Health | Conditions: Major Depressive Disorder | Phase 2 | Status: RECRUITING